We are live on ! Find out more
LEXX icon

Lexaria Bioscience
LEXX

15 hedge funds and large institutions have $1.67M invested in Lexaria Bioscience in 2022 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

0.1% less ownership

Funds ownership: 11.56% → 11.46% (-0.1%)

1% less capital invested

Capital invested by funds: $1.68M → $1.67M (-$8.48K)

6% less funds holding

Funds holding: 16 → 15 (-1)

40% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 5

Holders
15
Holders Change
-1
Holders Change %
-6.25%
% of All Funds
0.24%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
3
Reduced
5
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$62.3K
2
1832 Asset Management
1832 Asset Management
Ontario, Canada
+$6.43K
3
TRCT
Tower Research Capital (TRC)
New York
+$3.34K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$395

Top Sellers

Rank Fund Capital Flow
1
Two Sigma Investments
Two Sigma Investments
New York
-$32K
2
Citadel Advisors
Citadel Advisors
Florida
-$14.8K
3
UBS Group
UBS Group
Switzerland
-$1.94K
4
Renaissance Technologies
Renaissance Technologies
New York
-$933
5
CC
Centiva Capital
New York
-$467

LEXX Hedge Fund Activity: Q4 2022 in Review

15 of the 6,238 institutional investors tracked by Wall St. Rank reported a position in Lexaria Bioscience (LEXX) for Q4 2022, worth a combined $1.67M — down 0.5% from $1.68M a quarter earlier.

Fund positioning in LEXX was balanced in Q4 2022: 1 fund opened new positions, 1 closed out, 3 added to existing stakes and 5 trimmed.

The largest buyer was Susquehanna International Group, adding an estimated $62.3K. The largest seller was Two Sigma Investments, exiting entirely with an estimated $32K sold.

  • 15 institutional investors held Lexaria Bioscience (LEXX) as of Q4 2022, down from 16 in Q3 2022.
  • Funds reported $1.67M of Lexaria Bioscience stock for Q4 2022, down 0.5% quarter-over-quarter.
  • 1 fund opened new Lexaria Bioscience positions in Q4 2022 and 1 closed out, a net change of 0 holders.
  • The largest Lexaria Bioscience buyer in Q4 2022 was Susquehanna International Group, an estimated $62.3K added.
  • The largest Lexaria Bioscience seller in Q4 2022 was Two Sigma Investments, an estimated $32K sold.

Based on aggregated 13F filings for Q4 2022.